BACKGROUND & AIMS:Serotonin (5-hydroxytryptamine [5-HT]) has an important role in gastrointestinal function. LX1031 is an oral, locally acting, small molecule inhibitor of tryptophan hydroxylase (TPH). Local inhibition of TPH in the gastrointestinal tract might reduce mucosal production of serotonin (5-HT) and be used to treat patients with nonconstipating irritable bowel syndrome (IBS). METHODS: We evaluated 2 dose levels of LX1031 (250 mg or 1000 mg, given 4 times/day) in a 28-day, multicenter, randomized, double-blind, placebo-controlled study of 155 patients with nonconstipating IBS. 5-hydroxyindoleacetic acid (5-HIAA), a biomarker of pharmacodynamic activity, was measured in urine samples at baseline (24 hours after LX1031 administration), and at weeks 4 and 6 (n = 76). RESULTS: Each dose of LX1031 was safe and well-tolerated. The primary efficacy end point, relief of IBS pain and discomfort, improved significantly in patients given 1000 mg LX1031 (25.5%), compared with those given placebo, at week 1 (P = .018); with nonsignificant improvements at weeks 2, 3, and 4 (17.9%, 16.3%, and 11.6%, respectively). Symptom improvement correlated with a dose-dependent reduction in 5-HIAA, a marker for TPH inhibition, from baseline until week 4. This suggests the efficacy of LX1031 is related to the extent of inhibition of 5-HT biosynthesis. Stool consistency significantly improved, compared with the group given placebo, at weeks 1 and 4 (P < .01) and at week 2 (P < .001). CONCLUSIONS: In a phase 2 study, LX1031 was well tolerated, relieving symptoms and increasing stool consistency in patients with nonconstipating IBS. Symptom relief was associated with reduced levels of 5-HIAA in urine samples. This marker might be used to identify patients with nonconstipating IBS who respond to inhibitors of 5-HT synthesis.
RCT Entities:
BACKGROUND & AIMS:Serotonin (5-hydroxytryptamine [5-HT]) has an important role in gastrointestinal function. LX1031 is an oral, locally acting, small molecule inhibitor of tryptophan hydroxylase (TPH). Local inhibition of TPH in the gastrointestinal tract might reduce mucosal production of serotonin (5-HT) and be used to treat patients with nonconstipating irritable bowel syndrome (IBS). METHODS: We evaluated 2 dose levels of LX1031 (250 mg or 1000 mg, given 4 times/day) in a 28-day, multicenter, randomized, double-blind, placebo-controlled study of 155 patients with nonconstipating IBS. 5-hydroxyindoleacetic acid (5-HIAA), a biomarker of pharmacodynamic activity, was measured in urine samples at baseline (24 hours after LX1031 administration), and at weeks 4 and 6 (n = 76). RESULTS: Each dose of LX1031 was safe and well-tolerated. The primary efficacy end point, relief of IBS pain and discomfort, improved significantly in patients given 1000 mg LX1031 (25.5%), compared with those given placebo, at week 1 (P = .018); with nonsignificant improvements at weeks 2, 3, and 4 (17.9%, 16.3%, and 11.6%, respectively). Symptom improvement correlated with a dose-dependent reduction in 5-HIAA, a marker for TPH inhibition, from baseline until week 4. This suggests the efficacy of LX1031 is related to the extent of inhibition of 5-HT biosynthesis. Stool consistency significantly improved, compared with the group given placebo, at weeks 1 and 4 (P < .01) and at week 2 (P < .001). CONCLUSIONS: In a phase 2 study, LX1031 was well tolerated, relieving symptoms and increasing stool consistency in patients with nonconstipating IBS. Symptom relief was associated with reduced levels of 5-HIAA in urine samples. This marker might be used to identify patients with nonconstipating IBS who respond to inhibitors of 5-HT synthesis.
Authors: Michael Camilleri; Christopher N Andrews; Adil E Bharucha; Paula J Carlson; Irene Ferber; Debra Stephens; Thomas C Smyrk; Raul Urrutia; Jeroen Aerssens; Leen Thielemans; Hinrich Göhlmann; Ilse van den Wyngaert; Bernard Coulie Journal: Gastroenterology Date: 2006-11-17 Impact factor: 22.682
Authors: Francine Côté; Cécile Fligny; Elisa Bayard; Jean-Marie Launay; Michael D Gershon; Jacques Mallet; Guilan Vodjdani Journal: Proc Natl Acad Sci U S A Date: 2006-12-20 Impact factor: 11.205
Authors: Douglas A Drossman; Carolyn Blank Morris; Susan Schneck; Yuming J B Hu; Nancy J Norton; William F Norton; Stephan R Weinland; Christine Dalton; Jane Leserman; Shrikant I Bangdiwala Journal: J Clin Gastroenterol Date: 2009-07 Impact factor: 3.062
Authors: Kara Gross Margolis; Jennifer Vittorio; Maria Talavera; Karen Gluck; Zhishan Li; Alina Iuga; Korey Stevanovic; Virginia Saurman; Narek Israelyan; Martha G Welch; Michael D Gershon Journal: Am J Physiol Gastrointest Liver Physiol Date: 2017-08-03 Impact factor: 4.052
Authors: Ravinarayan Raghupathi; Michael D Duffield; Leah Zelkas; Adrian Meedeniya; Simon J H Brookes; Tiong Cheng Sia; David A Wattchow; Nick J Spencer; Damien J Keating Journal: J Physiol Date: 2013-10-07 Impact factor: 5.182